5 Αποτελέσματα
TECHNICAL FIELD
The present invention relates to a novel 1,3-dialkylurea derivative which has inhibitory effects on endopeptidase 24.11 and is useful as a therapeutic agent for cardiovascular diseases such as heart failure and hypertension, renal diseases such as renal failure, gastroenteric
BACKGROUND OF THE INVENTION
The present invention relates to the treatment of certain conditions using a compound of formula I or II, or a pharmaceutically acceptable salt thereof, as defined below. Specifically, the compounds of formulas I and II, and their pharmaceutically acceptable salts, as
FIELD OF THE INVENTION
The present invention relates to compounds that are A.sub.1 adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as asthma, diabetes, cardiac disorders, degenerative disorders of the central nervous system, and disease states
BACKGROUND OF THE INVENTION
Karanewsky et al. in U.S. Pat. Nos. 4,452,790 and 4,616,005 disclose that phosphonate compounds including those of the formula ##STR3## possess angiotensin converting enzyme inhibition activity and thus are useful as hypotensive agents.
Karanewsky et al. in U.S. Pat. No.
This application is a 371 of PCT/JP95/02236 filed Nov. 1, 1995, published as WO96/14293 May 17, 1996.
TECHNICAL FIELD
The present invention relates to novel 1,3-dialkylurea derivatives having a hydroxyl group which have inhibitory effects on endopeptidase 24.11 and are useful as therapeutic agents